Annexin Pharmaceuticals AB (OSTO:ANNX) ROCE % : -396.12% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Annexin Pharmaceuticals AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Annexin Pharmaceuticals AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -396.12%.

Annexin Pharmaceuticals AB ROCE % Historical Data

The historical data trend for Annexin Pharmaceuticals AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexin Pharmaceuticals AB ROCE % Chart

Annexin Pharmaceuticals AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-109.87

-272.28

-149.29

-105.94

-179.87

Annexin Pharmaceuticals AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-160.99	-214.33	-708.61	-602.07	-396.12

Annexin Pharmaceuticals AB ROCE % Calculation

Annexin Pharmaceuticals AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-44.039	/	( ( (36.679 - 6.526)	+	(26.763 - 7.949) )	/ 2 )
	=	-44.039	/	( (30.153	+	18.814)	/ 2 )
	=	-44.039	/	24.4835
	=	-179.87 %

Annexin Pharmaceuticals AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-49.832	/	( ( (26.763 - 7.949)	+	(11.811 - 5.465) )	/ 2 )
	=	-49.832	/	( ( 18.814	+	6.346 )	/ 2 )
	=	-49.832	/	12.58
	=	-396.12 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Annexin Pharmaceuticals AB (OSTO:ANNX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Annexin Pharmaceuticals AB ROCE % Related Terms

Thank you for viewing the detailed overview of Annexin Pharmaceuticals AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Annexin Pharmaceuticals AB (OSTO:ANNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexin Pharmaceuticals AB (OSTO:ANNX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

Q91:Germany

Address

Norrtullsgatan 6, Stockholm, SWE, SE-113 29

Website

https://www.annexinpharma.com

Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.